JP2018505139A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505139A5
JP2018505139A5 JP2017530742A JP2017530742A JP2018505139A5 JP 2018505139 A5 JP2018505139 A5 JP 2018505139A5 JP 2017530742 A JP2017530742 A JP 2017530742A JP 2017530742 A JP2017530742 A JP 2017530742A JP 2018505139 A5 JP2018505139 A5 JP 2018505139A5
Authority
JP
Japan
Prior art keywords
car
intracellular
signaling domain
cell signaling
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017530742A
Other languages
English (en)
Japanese (ja)
Other versions
JP6724009B2 (ja
JP2018505139A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/025047 external-priority patent/WO2016093878A1/en
Publication of JP2018505139A publication Critical patent/JP2018505139A/ja
Publication of JP2018505139A5 publication Critical patent/JP2018505139A5/ja
Application granted granted Critical
Publication of JP6724009B2 publication Critical patent/JP6724009B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017530742A 2014-12-08 2015-04-09 抗cd70キメラ抗原受容体 Active JP6724009B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088882P 2014-12-08 2014-12-08
US62/088,882 2014-12-08
PCT/US2015/025047 WO2016093878A1 (en) 2014-12-08 2015-04-09 Anti-cd70 chimeric antigen receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020109158A Division JP7128860B2 (ja) 2014-12-08 2020-06-24 抗cd70キメラ抗原受容体

Publications (3)

Publication Number Publication Date
JP2018505139A JP2018505139A (ja) 2018-02-22
JP2018505139A5 true JP2018505139A5 (enExample) 2018-05-24
JP6724009B2 JP6724009B2 (ja) 2020-07-15

Family

ID=52997584

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017530742A Active JP6724009B2 (ja) 2014-12-08 2015-04-09 抗cd70キメラ抗原受容体
JP2020109158A Active JP7128860B2 (ja) 2014-12-08 2020-06-24 抗cd70キメラ抗原受容体
JP2022092594A Active JP7574243B2 (ja) 2014-12-08 2022-06-07 抗cd70キメラ抗原受容体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020109158A Active JP7128860B2 (ja) 2014-12-08 2020-06-24 抗cd70キメラ抗原受容体
JP2022092594A Active JP7574243B2 (ja) 2014-12-08 2022-06-07 抗cd70キメラ抗原受容体

Country Status (12)

Country Link
US (3) US10689456B2 (enExample)
EP (3) EP3597663B1 (enExample)
JP (3) JP6724009B2 (enExample)
CN (2) CN113968913A (enExample)
AU (3) AU2015361261B2 (enExample)
CA (1) CA2970280A1 (enExample)
DK (1) DK3597663T3 (enExample)
ES (2) ES2745153T3 (enExample)
PL (1) PL3230310T3 (enExample)
PT (1) PT3230310T (enExample)
SI (1) SI3230310T1 (enExample)
WO (1) WO2016093878A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6724009B2 (ja) * 2014-12-08 2020-07-15 アメリカ合衆国 抗cd70キメラ抗原受容体
CN105949325B (zh) * 2016-07-08 2019-07-16 重庆精准生物技术有限公司 包含cd27胞内结构域的嵌合抗原受体、慢病毒载体及其应用
AU2017307610B2 (en) * 2016-08-04 2023-10-05 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
WO2019051047A1 (en) * 2017-09-07 2019-03-14 University Of Florida Research Foundation, Inc. CHIMERIC ANTIGEN RECEPTOR T-LYMPHOCYTES EXPRESSING THE INTERLEUKIN-8 RECEPTOR
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
JP7542441B2 (ja) * 2018-05-11 2024-08-30 クリスパー セラピューティクス アクチェンゲゼルシャフト 癌を治療するための方法及び組成物
KR20210038922A (ko) * 2018-08-02 2021-04-08 카이트 파마 인코포레이티드 키메라 항원 수용체 요법 t 세포 확장 동역학 및 그의 용도
CN109880802B (zh) * 2018-11-30 2022-12-13 北京美康基免生物科技有限公司 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用
EP3962498A4 (en) * 2019-04-30 2023-05-31 Memorial Sloan Kettering Cancer Center Combination therapies
US20200384278A1 (en) * 2019-06-04 2020-12-10 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Method for Combination Cold Atmospheric Plasma and CAR-T Therapy
US20220411478A1 (en) * 2019-09-16 2022-12-29 The General Hospital Corporation Cd70 targeted chimeric antigen receptor (car) t cells and uses thereof
MX2022008485A (es) * 2020-01-08 2022-08-02 Univ Texas Un metodo para modificar celulas asesinas naturales para dirigirse a tumores positivos a cd70.
CN111909966B (zh) * 2020-04-01 2021-09-21 苏州克睿基因生物科技有限公司 一种制备经修饰的免疫细胞的方法
AU2021377699A1 (en) 2020-11-13 2023-06-15 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022116952A1 (zh) * 2020-12-01 2022-06-09 苏州克睿基因生物科技有限公司 靶向cd70的抗原结合蛋白及其应用
EP4262825A1 (en) * 2020-12-15 2023-10-25 Universiteit Antwerpen Cell-based therapeutics targeting cd70
KR20230136184A (ko) * 2021-01-25 2023-09-26 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Cd70-양성 종양을 표적화하기 위한 cd27-세포외 도메인 car
US20220378829A1 (en) * 2021-05-12 2022-12-01 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating solid tumors
WO2023072307A1 (zh) * 2021-10-25 2023-05-04 重庆精准生物技术有限公司 一种靶向cd70的抗原结合片段、单链抗体和嵌合抗原受体及其应用
CN117924489A (zh) * 2022-01-19 2024-04-26 上海恒润达生生物科技股份有限公司 抗cd70纳米抗体及其用途
JP2025511914A (ja) * 2022-04-07 2025-04-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 操作されたナチュラルキラー細胞の活性化および増殖方法と抗体との組み合わせ
CN117126856A (zh) * 2022-05-20 2023-11-28 上海雅科生物科技有限公司 以bcma胞外结构域为标记的基因、多肽、重组表达载体、基因工程化细胞及其应用
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001049A2 (en) * 1990-07-13 1992-01-23 The General Hospital Corporation Cd53 cell surface antigen and use thereof
US7285267B2 (en) * 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US20070037165A1 (en) * 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
EP2483301A1 (en) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2012058460A2 (en) * 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN107188969B (zh) * 2011-04-08 2021-08-27 美国卫生和人力服务部 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
CA2863799C (en) 2012-02-22 2020-09-01 Matthew J. FRIGAULT Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
CN103483452B (zh) 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
WO2014055771A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
KR20210090298A (ko) * 2012-10-30 2021-07-19 에스퍼란스 파마슈티컬스, 인코포레이티드 항체/약물 컨쥬게이트 및 이의 사용 방법
CN104177499B (zh) * 2013-05-27 2019-01-08 上海雅科生物科技有限公司 一种嵌合抗原受体、编码基因、表达载体及其应用
JP6724009B2 (ja) * 2014-12-08 2020-07-15 アメリカ合衆国 抗cd70キメラ抗原受容体

Similar Documents

Publication Publication Date Title
JP2018505139A5 (enExample)
JP2016502512A5 (enExample)
JP2018531014A5 (enExample)
JP2018529380A5 (enExample)
JP2017537622A5 (enExample)
JP2018064568A5 (enExample)
Yip et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus
Kukkonen et al. L protein, the RNA-dependent RNA polymerase of hantaviruses
JP7611836B2 (ja) 抗原特異的t細胞の同定のための組成物と方法
BR112015009003A2 (pt) receptores de antígeno quiméricos
RU2014118555A (ru) Химерные антигенные рецепторы к cd22
EP4286407A3 (en) Anti-mutated kras t cell receptors
JP2016532693A5 (enExample)
Kalveram et al. Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKR
JP2017537627A5 (enExample)
JP2014500002A5 (enExample)
JP2017529851A5 (enExample)
JP2019528769A5 (enExample)
EP4424376A3 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
JP2019507180A5 (enExample)
JP2019519529A5 (enExample)
RU2017105515A (ru) Сигнальная система
JP2017535284A5 (enExample)
IL292650B1 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
JP2014239695A5 (enExample)